- Conditions
- HIV Infections
- Interventions
- rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced May 22, 2026, 12:01 AM EDT